People channel feed – Endpoints News

People channel feed

Backed by Novo and OrbiMed, Thierry Abribat hauls in $75M for biotech #3 — a transatlantic upstart focused on rare diseases

6 years ago

Jumping into growing queue of buyers, Vertex chief targets a slate of new and 'larger' deals ahead

6 years ago

PD-L1, CD47 and now CD24? Star Stanford I/O scientist Irv Weissman points to a ‘major’ new cancer target

6 years ago

Adaptimmune R&D chief Amado hits the exit amid a top-level shakeup as new CEO tries to revive ebbing enthusiasm

6 years ago

FDA chief backs 2 new pathways to spur drug importation — but analysts shrug it all off

6 years ago

Gilead chief Daniel O’Day isn’t done making headlines — with more R&D deals and lots of new hires to come

6 years ago

Verastem taps board director and Eli Lilly vet Brian Stuglik to right the commercial boat

6 years ago

Strapped for cash, Woodford's unraveling continues as listed fund considers kicking him out as manager

6 years ago

Wellcome Trust joins warning for no-deal Brexit, calls on Boris Johnson to cast R&D vision

6 years ago

Vertex rushes to assure Wall Street that Jeff Leiden is keeping a hand on the reins as one analyst questions succession plans

6 years ago

What makes Hal Barron tick? Look at the people he’s teaming up with at GSK

6 years ago

FDA’s Woodcock weighs in on role of NIH in drug development

6 years ago

Novartis, AstraZeneca vet Jonathan Symonds steers back to a top post in Big Pharma, this time at GSK

6 years ago

Breaking the death spiral: Hal Barron talks about transforming the moribund R&D culture at GSK in a critical year for the late-stage pipeline

6 years ago

After a decade, ViiV CSO John Pottage says it's time to step down — and he's handing the job to longtime colleague Kim Smith

6 years ago

Biotech unicorns first to go as Neil Woodford auctions assets off suspended fund — report

6 years ago

The $1.1M goodbye: Gilead CSO John McHutchison is out as Daniel O’Day shakes up the senior team

6 years ago

Inovio axes staff, chops R&D programs in chase for elusive commercial win — though there's still a lot on their plate

6 years ago

Part club, part guide, part landlord: Arie Belldegrun is blueprinting a string of bespoke biotech complexes in global boomtowns — starting with Boston

6 years ago

Takeda's translational cell therapy group revs up for a race to the clinic with off-the-shelf CAR-T

6 years ago

GSK to tap Jonathan Symonds as chairman, leveraging Big Pharma experience for consumer biz deal

6 years ago

Fresh out of Eli Lilly, Christi Shaw surfaces as Daniel O'Day's new CEO at CAR-T pioneer Kite

6 years ago

Eli Lilly's Christi Shaw bows out of top post at the Bio-Medicines unit

6 years ago

No clear answers: Yes, recent actions against Chinese American scientists do pose a threat — but maybe those official concerns about espionage are valid too

6 years ago

First page Previous page 75 76 777879 80 81 Next page Last page